Next Article in Journal
The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments
Next Article in Special Issue
Clinical Implication of Liquid Biopsy in Colorectal Cancer Patients Treated with Metastasectomy
Previous Article in Journal
Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center
Previous Article in Special Issue
Neo-Fs Index: A Novel Immunohistochemical Biomarker Panel Predicts Survival and Response to Anti-Angiogenetic Agents in Clear Cell Renal Cell Carcinoma
 
 
Article

Characterization of Cell-Bound CA125 on Immune Cell Subtypes of Ovarian Cancer Patients Using a Novel Imaging Platform

1
PNP Research Corporation, Drury, MA 01343, USA
2
Brigham and Women’s Hospital, Department of Obstetrics, Gynecology and Reproductive Biology, Boston, MA 02115, USA
3
Thorlabs Imaging Systems, Sterling, VA 20166, USA
4
Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, WI 53706, USA
5
Massachusetts General Hospital, Wellman Center for Photomedicine, Boston, MA 02114, USA
6
Private Researcher, Philadelphia, PA 98516, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Kylie Gorringe
Cancers 2021, 13(9), 2072; https://doi.org/10.3390/cancers13092072
Received: 17 February 2021 / Revised: 14 April 2021 / Accepted: 22 April 2021 / Published: 25 April 2021
(This article belongs to the Collection Cancer Biomarkers)
High-grade serous ovarian cancer is a fatal disease typically detected at an advanced stage when options for effective treatment are significantly limited. The lack of a screening modality to identify ovarian cancer in its early stage continues to be a major impediment in the management of this malignancy. The serum biomarker CA125, a repeating peptide epitope present in the sialomucin, MUC16, is unsuitable as a screening test. We have demonstrated that immune cells of ovarian cancer patients capture miniscule amounts of CA125 on their cell surface. Here, we report an automated, sensitive, alignment-free microscopy platform to qualitatively and quantitatively assess the low-abundance binding of CA125 to circulating leucocyte subsets. Through a comparison of the CA125 levels on immune cell subsets of ovarian cancer patients versus healthy donors, we demonstrate that our new technique can serve as a novel diagnostic platform for detection and monitoring of ovarian cancer.
MUC16, a sialomucin that contains the ovarian cancer biomarker CA125, binds at low abundance to leucocytes via the immune receptor, Siglec-9. Conventional fluorescence-based imaging techniques lack the sensitivity to assess this low-abundance event, prompting us to develop a novel “digital” optical cytometry technique for qualitative and quantitative assessment of CA125 binding to peripheral blood mononuclear cells (PBMC). Plasmonic nanoparticle labeled detection antibody allows assessment of CA125 at the near-single molecule level when bound to specific immune cell lineages that are simultaneously identified using multiparameter fluorescence imaging. Image analysis and deep learning were used to quantify CA125 per each cell lineage. PBMC from treatment naïve ovarian cancer patients (N = 14) showed higher cell surface abundance of CA125 on the aggregate PBMC population as well as on NK (p = 0.013), T (p < 0.001) and B cells (p = 0.024) compared to circulating lymphocytes of healthy donors (N = 7). Differences in CA125 binding to monocytes or NK-T cells between the two cohorts were not significant. There was no correlation between the PBMC-bound and serum levels of CA125, suggesting that these two compartments are not in stoichiometric equilibrium. Understanding where and how subset-specific cell-bound surface CA125 takes place may provide guidance towards a new diagnostic biomarker in ovarian cancer. View Full-Text
Keywords: ovarian cancer; CA125; MUC16; Siglec-9; surface plasmon resonance; multiparameter imaging; deep learning; lymphocyte ovarian cancer; CA125; MUC16; Siglec-9; surface plasmon resonance; multiparameter imaging; deep learning; lymphocyte
Show Figures

Figure 1

MDPI and ACS Style

González, G.; Lakatos, K.; Hoballah, J.; Fritz-Klaus, R.; Al-Johani, L.; Brooker, J.; Jeong, S.; Evans, C.L.; Krauledat, P.; Cramer, D.W.; Hoffman, R.A.; Hansen, W.P.; Patankar, M.S. Characterization of Cell-Bound CA125 on Immune Cell Subtypes of Ovarian Cancer Patients Using a Novel Imaging Platform. Cancers 2021, 13, 2072. https://doi.org/10.3390/cancers13092072

AMA Style

González G, Lakatos K, Hoballah J, Fritz-Klaus R, Al-Johani L, Brooker J, Jeong S, Evans CL, Krauledat P, Cramer DW, Hoffman RA, Hansen WP, Patankar MS. Characterization of Cell-Bound CA125 on Immune Cell Subtypes of Ovarian Cancer Patients Using a Novel Imaging Platform. Cancers. 2021; 13(9):2072. https://doi.org/10.3390/cancers13092072

Chicago/Turabian Style

González, Germán, Kornél Lakatos, Jawad Hoballah, Roberta Fritz-Klaus, Lojain Al-Johani, Jeff Brooker, Sinyoung Jeong, Conor L. Evans, Petra Krauledat, Daniel W. Cramer, Robert A. Hoffman, W. Peter Hansen, and Manish S. Patankar. 2021. "Characterization of Cell-Bound CA125 on Immune Cell Subtypes of Ovarian Cancer Patients Using a Novel Imaging Platform" Cancers 13, no. 9: 2072. https://doi.org/10.3390/cancers13092072

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop